Engineering stem cell resistance to HIV for two-pronged approach to HIV-associated lymphoma

Anti-CD38 antibody SAR may be new "blockbuster" treatment for aggressive multiple myeloma

Investigational antibody demonstrates efficacy, safety for patients with aggressive multiple myeloma in phase I study

HIV-associated lymphoma responds well to stem cell transplantation

Relapsed multiple myeloma responds to combination therapy with daratumumab

Daratumumab plus standard treatment improves outcomes in relapsed, hard-to-treat multiple myeloma in phase I study

Stem cell transplantation safe for patients with HIV-associated lymphoma

Carfilzomib represents potent, effective addition to standard multiple myeloma therapy in phase III study

Post-transplant survival boosted by brentuximab vedotin in lymphoma

Brentuximab vedotin prolongs post-transplant survival in hard-to-treat lymphoma patients in phase III study

Children with aggressive leukaemia experiencing remission with T cell therapy

ASPIRE study: Carfilzomib potent addition to multiple myeloma therapy